FIGURE 7.

Mitochondria status and total anti-oxidant ability assessments. (A) Specific formulation of MitoTracker^® Red CM-H₂XRos was used to identify cells with diminished mitochondria oxidation ability. Control MDCK cells showed weak signal similar to those of HNK-treated and cisplatin-HNK co-incubation cells while cisplatin-treated cells exhibited strong fluorescent signal indicating diminished oxidation status of mitochondria in these cells. (B) Quantification of cells with diminished oxidation status demonstrated significant increase of cells with diminished oxidation status in cisplatin-treated group, and this negative effect can be attenuated when 10 μM HNK was co-incubated in the presence of 10 μM cisplatin. (C) Total anti-oxidant capability (TAC) assay was performed to access cellular anti-oxidant ability. Kinetic TAC measurement at the first 30 min after the initiation of the assay showed a clear reduction of total antioxidant capacity in cisplatin-treated cells (in red). Based on endpoint measurement, when compared with vehicle control, cisplatin-treated cells showed sharp reduction on TAC (69% reduction), and this reduction was attenuated when Honokiol was con-present in the incubation medium. Data were presented as mean ± SEM, and representative images were presented. a,b indicated significant (p < 0.05) difference between groups.